IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

Core Insights - IO Biotech has been recognized as the 9th most innovative company in the biotechnology category by Fast Company for its development of immune-modulatory therapeutic cancer vaccines [1][2][4] - The company is focused on creating off-the-shelf cancer vaccines that can be available at the time of patient diagnosis, aiming to change the oncology treatment paradigm [2][4] - IO Biotech's T-win® platform is designed to target both tumor cells and immune-suppressive cells in the tumor microenvironment, potentially leading to improved patient outcomes [2][4][6] Company Overview - IO Biotech is a clinical-stage biopharmaceutical company headquartered in Copenhagen, Denmark, with a US office in New York [6] - The company is advancing its lead investigational cancer vaccine candidate, Cylembio® (imsapepimut and etimupepimut, adjuvanted), which is currently in a global Phase 3 clinical trial for advanced melanoma [4][6] - Cylembio® has received Breakthrough Therapy Designation from the US FDA for the treatment of advanced melanoma in combination with Merck's KEYTRUDA® (pembrolizumab) [6] Industry Recognition - Fast Company's list of the Most Innovative Companies is a highly anticipated feature that evaluates thousands of submissions to recognize organizations driving progress across various industries [3] - The recognition highlights companies that are leveraging innovative technologies and strategies to enhance customer experiences and introduce vital competition in their sectors [4][3]